Botulinum A Toxin (OnabotulinumtoxinA) Use in Mexican Pediatric Population With Spasticity Associated With Cerebral Palsy: Phase IV, Observational, Non-Interventional, Prospective, Multicenter Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Spasticity
- Sponsor
- AbbVie
- Enrollment
- 107
- Locations
- 8
- Primary Endpoint
- Preventive Pain Management Technique
- Status
- Completed
- Last Updated
- 10 months ago
Overview
Brief Summary
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe. This study will assess how effective OnabotulinumtoxinA is in treating pediatric participants with Spasticity. Change in disease activity will be evaluated.
OnabotulinumtoxinA is approved drug for treatment of Spasticity. Approximately 106 pediatric participants aged 2-17 years with spasticity associated with cerebral palsy will be enrolled in approximately 10 sites across Mexico.
Participants will receive OnabotulinumtoxinA as prescribed by their physician in accordance to local label and followed for 12 months.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits to a hospital or clinic in their routine practice.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Unilateral/bilateral, upper/lower limb spasticity associated with cerebral palsy.
- •Naïve to OnabotulinumtoxinA treatment and who, according to medical and to the standard clinical practice criteria, will receive OnabotulinumtoxinA.
- •Treated only with stable doses of short-acting muscle relaxants can be included in the study, at the investigator's discretion, for at least 30 days prior to treatment starting, under the concept that at the time the steady state of the drug (stable plasma concentrations) will theoretically have been reached.
- •Under adjuvant treatment with orthoses and other orthopedic devices can be included in the study.
- •Participants with physio/physical therapy can be included.
Exclusion Criteria
- •Previously treated with botulinum toxin for spasticity related to cerebral palsy.
- •Diagnosed with Eaton-Lambert syndrome, myasthenia gravis, or other neurological diseases with compromised neuromuscular transmission.
- •History of hypersensitivity to the study drug or to any of the excipients in the formulation.
- •Evidence of inflammation or infection in the anatomical region selected by the investigator for the study drug administration.
- •Participants under treatment with drugs that interfere with neuromuscular transmission which, at the investigator's discretion, contraindicate OnabotulinumtoxinA concomitant administration.
- •Have had orthopedic surgery in the segment to be infiltrated in the 12 months prior to drug application.
Outcomes
Primary Outcomes
Preventive Pain Management Technique
Time Frame: Up to 12 months
Type of method used to control procedural pain will be assessed.
Re-administration Interval
Time Frame: Up to 12 months
Re-administration interval is defined as number of days between drug application and previous application.
Total Dose Per Kilogram
Time Frame: Up to 12 months
OnabotulinumtoxinA total dose applied at each visit, divided by patient's body weight will be assessed.
Dose Per Muscle
Time Frame: Up to 12 months
OnabotulinumtoxinA dose applied to each muscle, regardless of punctures' number on that muscle will be assessed.
Method to Locate Application Site
Time Frame: Up to 12 months
Type of method used to identify muscle and treatment application site will be assessed.
Absolute Total Dose
Time Frame: Up to 12 months
OnabotulinumtoxinA total dose applied at visit will be assessed.
Needle Gauge
Time Frame: Up to 12 months
Needle gauge is defined as diameter of needle thickness with which study treatment is applied.
Application Sites Number Per Muscle
Time Frame: Up to 12 months
Number of puncture sites per muscle will be assessed.
Needle Length
Time Frame: Up to 12 months
Needle length is defined as distance from the needle base to the needle bevel tip.